Rate and causes of noncompliance with disease-modifying antirheumatic drug regimens in patients with rheumatoid arthritis

Katchamart, Wanruchada; Narongroeknawin, Pongthorn; Sukprasert, Ngamsiree; Chanapai, Wanwisa; Srisomnuek, Ananya

doi:10.1007/s10067-020-05409-5

Cited by 8 publications

(13 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current study, there was no relationship between the presence of amyloidosis and treatment adherence. Furthermore, the adherence rate is lower than the studies that assessed adherence in other rheumatologic diseases (12,23). The rate of the patients, who were adherent to biological drugs, was 59.3% in rheumatoid arthritis, 62.5% in psoriatic arthritis and 76.2% in ankylosing spondylitis (24).…”

Section: Discussionmentioning

confidence: 90%

Non-adherence to colchicine treatment is a common misevaluation in familial Mediterranean fever

Tekgöz¹,

Çolak²,

Çınar³

et al. 2021

Turk J Med Sci

View full text Add to dashboard Cite

Background: Familial Mediterranean fever (FMF) is a hereditary autoinflammatory disease that requires lifelong colchicine treatment. Colchicine is the mainstay of the treatment which decreases the frequency and the severity of recurrent FMF attacks, also, prevents the development of amyloidosis. This study aimed to investigate the rates of colchicine treatment adherence in patients with FMF and the factors related to treatment non-adherence. Materials and methods: This observational study was conducted with 179 patients with FMF between November 2018 and April 2019 in a tertiary rheumatology outpatient clinic. The sociodemographic and clinical data were recorded. Compliance Questionnaire on Rheumatology (CQR) was used to assess the treatment adherence and the Beliefs About Medicines Questionnaire (BMQ-T) was used to assess a patient's beliefs about colchicine. The factors associated with adherence to the treatment were evaluated. Results:The study included 113 male (63.1%) and 66 (36.9%) female patients with a mean age of 30 (25-44) years. The rate of the patients who declared regular colchicine usage was 66.5%. The frequency of non-adherent patients was 83.8% according to CQR. Treatment adherence was better in patients with comorbid diseases than those without (41.4% vs. 22%, respectively, p = 0.028). The frequency of married patients in the adherent group (72.4%) was higher than the non-adherent group (47.3%) (p = 0.013). The colchicine dose used in the adherent group was 1.5 (1.3-1.8) mg/day, whereas it was 1.5 (1.0-1.5) mg/day in the non-adherent group (p = 0.033). The 2 adherence rate was rising with increasing scores of BMQ-T Specific Necessity. As the scores of BMQ-T General Overuse and General Harm increased, non-adherence to colchicine increased. Conclusion:Evaluating adherence to colchicine treatment with objective methods is crucial to ensure sufficient treatment and prevent amyloidosis. Determining beliefs about colchicine may increase patients' adherence to treatment.

show abstract

Section: Discussionmentioning

confidence: 90%

Non-adherence to colchicine treatment is a common misevaluation in familial Mediterranean fever

Tekgöz¹,

Çolak²,

Çınar³

et al. 2021

Turk J Med Sci

View full text Add to dashboard Cite

show abstract

“…Non-adherence with medication, in some cases, is actually triggered by a patient's inadequate awareness of the reason a new drug is being added, and what they may expect when taking a new medication. One study showed that 65% of the non-adherence associated with initiating MTX occurred because patients were not aware of its actual usage or why they were taking the medication [ 3 ]. This necessitates the importance of appropriate and sufficient patient education, especially when creating treatment plans that require the use of medications.…”

Section: Reviewmentioning

confidence: 99%

“…A number of patient-related factors have been found to influence medication adherence in RA patients. In a prospective cohort study involving 443 adult, Thai RA patients Katchamart et al found that age and functional status as measured by the Health Assessment Questionnaire (HAQ) were significantly related to medication nonadherence [ 3 ]. Older age and more functional impairment significantly decreased the risk of nonadherence (age (risk ratio, 0.98; 95% CI, 0.96-0.99; p, 0.048) and HAQ (risk ratio, 0.62; 95% CI, 0.39-0.98; p, 0.041)).…”

Section: Reviewmentioning

confidence: 99%

“…Therapies for RA include analgesics, NSAIDS, glucocorticoids, and disease-modifying antirheumatic medications (DMARDs) [ 3 ]. DMARDs reduce disease activity and radiographic progression while also improving long-term functional outcomes [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

“…DMARDs reduce disease activity and radiographic progression while also improving long-term functional outcomes [ 4 ]. The use of a conventional DMARD-methotrexate (MTX), sulfasalazine, an antimalarial agent, or leflunomide-as first-line medication is frequently recommended by institutions worldwide [ 3 ]. Optimal MTX use has a number of advantages including disease management, a reduction in the need for more expensive biologic treatments, and an improvement in the patient's overall outcome [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

An Overview on Causes of Nonadherence in the Treatment of Rheumatoid Arthritis: Its Effect on Mortality and Ways to Improve Adherence

Chowdhury¹,

Dutta²,

Noel³

et al. 2022

Cureus

View full text Add to dashboard Cite

Rheumatoid arthritis is one of the most prevalent musculoskeletal disorders that, when insufficiently treated, results in detrimental sequelae including joint damage and reduced quality of life. Poor patient adherence to medication is a significant blockade to effective management. The purpose of this review is to highlight and discuss the factors responsible for defiance of antirheumatic medication and ways to overcome these barriers. Education level, health literacy, cohabitation status, multi-morbidities, complicated drug regimen, intermittent co-payments, prescribed regimen adverse effects, and cognitive impairment are a few among many common barrier factors leading to poorer outcomes in rheumatoid arthritis. While there is an abundance of inhibitory factors leading to worsening disease progression, they each can be easily dealt with an effective approach at the beginning or during the treatment course to ensure a better outcome.

show abstract

Medication adherence and predictive factors among patients with rheumatoid arthritis: A COM-B model guided structural equation modeling analysis

Gong,

Dong,

Zhang

et al. 2024

Patient Education and Counseling

View full text Add to dashboard Cite

Rate and causes of noncompliance with disease-modifying antirheumatic drug regimens in patients with rheumatoid arthritis

Cited by 8 publications

References 29 publications

Non-adherence to colchicine treatment is a common misevaluation in familial Mediterranean fever

Non-adherence to colchicine treatment is a common misevaluation in familial Mediterranean fever

An Overview on Causes of Nonadherence in the Treatment of Rheumatoid Arthritis: Its Effect on Mortality and Ways to Improve Adherence

Medication adherence and predictive factors among patients with rheumatoid arthritis: A COM-B model guided structural equation modeling analysis

Contact Info

Product

Resources

About